1c1z › Citations

Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome.

Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R
EMBO J 18 6228-39 (1999)
Cited: 187 times
EuropePMC logo PMID: 10562535

Abstract

The high affinity of human plasma beta2-glycoprotein I (beta(2)GPI), also known as apolipoprotein-H (ApoH), for negatively charged phospholipids determines its implication in a variety of physiological pathways, including blood coagulation and the immune response. beta(2)GPI is considered to be a cofactor for the binding of serum autoantibodies from antiphospholipid syndrome (APS) and correlated with thrombosis, lupus erythematosus and recurrent fetal loss. We solved the beta(2)GPI structure from a crystal form with 84% solvent and present a model containing all 326 amino acid residues and four glycans. The structure reveals four complement control protein modules and a distinctly folding fifth C-terminal domain arranged like beads on a string to form an elongated J-shaped molecule. Domain V folds into a central beta-spiral of four antiparallel beta-sheets with two small helices and an extended C-terminal loop region. It carries a distinct positive charge and the sequence motif CKNKEKKC close to the hydrophobic loop composed of residues LAFW (313-316), resulting in an excellent counterpart for interactions with negatively charged amphiphilic substances. The beta(2)GPI structure reveals potential autoantibody-binding sites and supports mutagenesis studies where Trp316 and CKNKEKKC have been found to be essential for the phospholipid-binding capacity of beta(2)GPI.

Reviews - 1c1z mentioned but not cited (2)

  1. Control of blood proteins by functional disulfide bonds. Butera D, Cook KM, Chiu J, Wong JW, Hogg PJ. Blood 123 2000-2007 (2014)
  2. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. McDonnell T, Wincup C, Buchholz I, Pericleous C, Giles I, Ripoll V, Cohen H, Delcea M, Rahman A. Blood Rev. 39 100610 (2020)

Articles - 1c1z mentioned but not cited (21)

  1. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Grace CR, Perrin MH, DiGruccio MR, Miller CL, Rivier JE, Vale WW, Riek R. Proc. Natl. Acad. Sci. U.S.A. 101 12836-12841 (2004)
  2. Ensemble refinement of protein crystal structures: validation and application. Levin EJ, Kondrashov DA, Wesenberg GE, Phillips GN. Structure 15 1040-1052 (2007)
  3. Amphipathic α-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles. Fukuhara T, Wada M, Nakamura S, Ono C, Shiokawa M, Yamamoto S, Motomura T, Okamoto T, Okuzaki D, Yamamoto M, Saito I, Wakita T, Koike K, Matsuura Y. PLoS Pathog. 10 e1004534 (2014)
  4. Redox control of β2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Giannakopoulos B, Hughes WE, Hogg PJ, Krilis SA. J. Thromb. Haemost. 8 1754-1762 (2010)
  5. Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V. Segers K, Sperandio O, Sack M, Fischer R, Miteva MA, Rosing J, Nicolaes GA, Villoutreix BO. Proc. Natl. Acad. Sci. U.S.A. 104 12697-12702 (2007)
  6. Membrane binding of beta2-glycoprotein I can be described by a two-state reaction model: an atomic force microscopy and surface plasmon resonance study. Gamsjaeger R, Johs A, Gries A, Gruber HJ, Romanin C, Prassl R, Hinterdorfer P. Biochem. J. 389 665-673 (2005)
  7. Interpretation of ensembles created by multiple iterative rebuilding of macromolecular models. Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Adams PD, Moriarty NW, Zwart P, Read RJ, Turk D, Hung LW. Acta Crystallogr. D Biol. Crystallogr. 63 597-610 (2007)
  8. Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship. Matsuura E, Inagaki J, Kasahara H, Yamamoto D, Atsumi T, Kobayashi K, Kaihara K, Zhao D, Ichikawa K, Tsutsumi A, Yasuda T, Triplett DA, Koike T. Int. Immunol. 12 1183-1192 (2000)
  9. A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome. Kolyada A, Lee CJ, De Biasio A, Beglova N. PLoS ONE 5 e15345 (2010)
  10. Characterization of a reduced form of plasma plasminogen as the precursor for angiostatin formation. Butera D, Wind T, Lay AJ, Beck J, Castellino FJ, Hogg PJ. J. Biol. Chem. 289 2992-3000 (2014)
  11. Evaluating the conformation of recombinant domain I of β(2)-glycoprotein I and its interaction with human monoclonal antibodies. Pericleous C, Miles J, Esposito D, Garza-Garcia A, Driscoll PC, Lambrianides A, Latchman D, Isenberg D, Rahman A, Ioannou Y, Giles I. Mol. Immunol. 49 56-63 (2011)
  12. Single-residue posttranslational modification sites at the N-terminus, C-terminus or in-between: To be or not to be exposed for enzyme access. Sirota FL, Maurer-Stroh S, Eisenhaber B, Eisenhaber F. Proteomics 15 2525-2546 (2015)
  13. Structural insights into recognition of beta2-glycoprotein I by the lipoprotein receptors. Beglov D, Lee CJ, De Biasio A, Kozakov D, Brenke R, Vajda S, Beglova N. Proteins 77 940-949 (2009)
  14. Automatically Fixing Errors in Glycoprotein Structures with Rosetta. Frenz B, Rämisch S, Borst AJ, Walls AC, Adolf-Bryfogle J, Schief WR, Veesler D, DiMaio F. Structure 27 134-139.e3 (2019)
  15. Cardiolipin interacts with beta-2-glycoprotein I and forms an open conformation-Mechanisms analyzed using hydrogen/deuterium exchange. Tang KT, Wu TY, Chen HH, Lin CC, Hsu YH. Protein Sci 30 927-939 (2021)
  16. Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. Buchholz I, McDonnell T, Nestler P, Tharad S, Kulke M, Radziszewska A, Ripoll VM, Schmidt F, Hammer E, Toca-Herrera JL, Rahman A, Delcea M. Sci Rep 11 4542 (2021)
  17. Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops. Kolyada A, Barrios DA, Beglova N. Antibodies (Basel) 6 (2017)
  18. High resolution structure of human apolipoprotein (a) kringle IV type 2: beyond the lysine binding site. Santonastaso A, Maggi M, De Jonge H, Scotti C. J Lipid Res 61 1687-1696 (2020)
  19. Identification of the binding site for fondaparinux on Beta2-glycoprotein I. Kolyada A, De Biasio A, Beglova N. Biochim. Biophys. Acta 1834 2080-2088 (2013)
  20. Interactions between Beta-2-Glycoprotein-1 and Phospholipid Bilayer-A Molecular Dynamic Study. Kruszewska N, Domino K, Drelich R, Urbaniak W, Petelska AD. Membranes (Basel) 10 E396 (2020)
  21. The J-elongated conformation of β2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. Ruben E, Planer W, Chinnaraj M, Chen Z, Zuo X, Pengo V, De Filippis V, Alluri RK, McCrae KR, Macor P, Tedesco F, Pozzi N. J Biol Chem 295 10794-10806 (2020)


Reviews citing this publication (60)

  1. The pathogenesis of the antiphospholipid syndrome. Giannakopoulos B, Krilis SA. N. Engl. J. Med. 368 1033-1044 (2013)
  2. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Laburthe M, Couvineau A, Tan V. Peptides 28 1631-1639 (2007)
  3. Antiphospholipid syndrome infectious origin. Blank M, Asherson RA, Cervera R, Shoenfeld Y. J. Clin. Immunol. 24 12-23 (2004)
  4. β(2) -Glycoprotein I: evolution, structure and function. de Groot PG, Meijers JC. J. Thromb. Haemost. 9 1275-1284 (2011)
  5. Getting to the Outer Leaflet: Physiology of Phosphatidylserine Exposure at the Plasma Membrane. Bevers EM, Williamson PL. Physiol. Rev. 96 605-645 (2016)
  6. Molecular pathogenesis of the antiphospholipid syndrome. Rand JH. Circ. Res. 90 29-37 (2002)
  7. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. Arnout J, Vermylen J. J. Thromb. Haemost. 1 931-942 (2003)
  8. Pathophysiology of the antiphospholipid syndrome. de Groot PG, Derksen RH. J. Thromb. Haemost. 3 1854-1860 (2005)
  9. Post-translational control of protein function by disulfide bond cleavage. Cook KM, Hogg PJ. Antioxid. Redox Signal. 18 1987-2015 (2013)
  10. Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations. Blank M, Shoenfeld Y. Clin. Immunol. 112 190-199 (2004)
  11. beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. Bas de Laat H, Derksen RH, de Groot PG. Clin. Immunol. 112 161-168 (2004)
  12. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Urbanus RT, Derksen RH, de Groot PG. Blood Rev. 22 93-105 (2008)
  13. How do antiphospholipid antibodies bind beta2-glycoprotein I? Giles IP, Isenberg DA, Latchman DS, Rahman A. Arthritis Rheum. 48 2111-2121 (2003)
  14. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Bolanos-Garcia VM, Miguel RN. Prog. Biophys. Mol. Biol. 83 47-68 (2003)
  15. Autoantibodies directed against domain I of beta2-glycoprotein I. de Laat B, de Groot PG. Curr Rheumatol Rep 13 70-76 (2011)
  16. The antiphospholipid syndrome. Rand JH. Annu. Rev. Med. 54 409-424 (2003)
  17. Annexin A2: biology and relevance to the antiphospholipid syndrome. Cockrell E, Espinola RG, McCrae KR. Lupus 17 943-951 (2008)
  18. Vaccines, adjuvants and autoimmunity. Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Pharmacol. Res. 100 190-209 (2015)
  19. Infections and vaccines in the etiology of antiphospholipid syndrome. Cruz-Tapias P, Blank M, Anaya JM, Shoenfeld Y. Curr Opin Rheumatol 24 389-393 (2012)
  20. Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Di Simone N, Meroni PL, D'Asta M, Di Nicuolo F, D'Alessio MC, Caruso A. Hum. Reprod. Update 13 189-196 (2007)
  21. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Di Simone N, Luigi MP, Marco D, Fiorella DN, Silvia D, Clara DM, Alessandro C. Ann. N. Y. Acad. Sci. 1108 505-514 (2007)
  22. Systemic lupus erythematosus, atherosclerosis, and autoantibodies. Zampieri S, Iaccarino L, Ghirardello A, Tarricone E, Arienti S, Sarzi-Puttini P, Gambari P, Doria A. Ann. N. Y. Acad. Sci. 1051 351-361 (2005)
  23. Antiphospholipid antibodies--we are not quite there yet. Urbanus RT, de Groot PG. Blood Rev. 25 97-106 (2011)
  24. Control of mature protein function by allosteric disulfide bonds. Azimi I, Wong JW, Hogg PJ. Antioxid. Redox Signal. 14 113-126 (2011)
  25. A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. Giles IP, Haley JD, Nagl S, Isenberg DA, Latchman DS, Rahman A. Semin. Arthritis Rheum. 32 246-265 (2003)
  26. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Chighizola CB, Gerosa M, Meroni PL. Curr Rheumatol Rep 16 402 (2014)
  27. Antiphospholipid syndrome: antibodies and antigens. Roubey RA. Curr. Opin. Hematol. 7 316-320 (2000)
  28. Beta2-glycoprotein I and its clinical significance: from gene sequence to protein levels. Sodin-Semrl S, Rozman B. Autoimmun Rev 6 547-552 (2007)
  29. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Ortel TL. Am. J. Hematol. 87 Suppl 1 S75-81 (2012)
  30. Beta2-glycoprotein I, anti-beta2-glycoprotein I, and fibrinolysis. Yasuda S, Atsumi T, Ieko M, Koike T. Thromb. Res. 114 461-465 (2004)
  31. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. J. Thromb. Haemost. 9 Suppl 1 275-282 (2011)
  32. Anti-β2-glycoprotein I antibodies. Willis R, Pierangeli SS. Ann. N. Y. Acad. Sci. 1285 44-58 (2013)
  33. Antiphospholipid syndrome and heparin-induced thrombocytopenia: update on similarities and differences. Gruel Y. J. Autoimmun. 15 265-268 (2000)
  34. Beta 2-glycoprotein I-anti-beta 2-glycoprotein I interaction. Koike T, Ichikawa K, Atsumi T, Kasahara H, Matsuura E. J. Autoimmun. 15 97-100 (2000)
  35. The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin. Bevers EM, Zwaal RF, Willems GM. Clin. Immunol. 112 150-160 (2004)
  36. Update on antiphospholipid antibodies. Roubey RA. Curr Opin Rheumatol 12 374-378 (2000)
  37. Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies. Atsumi T, Amengual O, Yasuda S, Matsuura E, Koike T. Autoimmunity 38 377-381 (2005)
  38. Thiol-Disulfide Exchange Reactions in the Mammalian Extracellular Environment. Yi MC, Khosla C. Annu Rev Chem Biomol Eng 7 197-222 (2016)
  39. Antibodies against domain I of β2-glycoprotein I: the one and only? Pelkmans L, de Laat B. Lupus 21 769-772 (2012)
  40. Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis. Sherer Y, Shoenfeld Y. Curr Atheroscler Rep 3 328-333 (2001)
  41. Antiphospholipid syndrome: insights from animal models. Sherer Y, Shoenfeld Y. Curr. Opin. Hematol. 7 321-324 (2000)
  42. New insights into the biology and pathobiology of beta2-glycoprotein I. Giannakopoulos B, Mirarabshahi P, Krilis SA. Curr Rheumatol Rep 13 90-95 (2011)
  43. Atherogenic antiphospholipid antibodies in antiphospholipid syndrome. Kobayashi K, Lopez LR, Matsuura E. Ann. N. Y. Acad. Sci. 1108 489-496 (2007)
  44. Beta-2 glycoprotein I and its role in antiphospholipid syndrome-lessons from knockout mice. Miyakis S, Robertson SA, Krilis SA. Clin. Immunol. 112 136-143 (2004)
  45. Beta2-glycoprotein I and atherosclerosis. Harats D, George J. Curr. Opin. Lipidol. 12 543-546 (2001)
  46. Conformation of beta2glycoprotein I and its effect on coagulation. Ninivaggi M, Kelchtermans H, Lindhout T, de Laat B. Thromb. Res. 130 Suppl 1 S33-6 (2012)
  47. Structure-function studies on beta 2-glycoprotein I. de Groot G PG, Bouma B, Lutters BC, Simmelink MJ, Derksen RH, Gros P. J. Autoimmun. 15 87-89 (2000)
  48. Antiphosphatidylserine antibodies and reproductive failure. Blank M, Shoenfeld Y. Lupus 13 661-665 (2004)
  49. Biosensor analyses of serum autoantibodies: application to antiphospholipid syndrome and systemic lupus erythematosus. Thaler M, Buhl A, Welter H, Schreiegg A, Kehrel M, Alber B, Metzger J, Luppa PB. Anal Bioanal Chem 393 1417-1429 (2009)
  50. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Matsuura E, Shen L, Matsunami Y, Quan N, Makarova M, Geske FJ, Boisen M, Yasuda S, Kobayashi K, Lopez LR. Lupus 19 379-384 (2010)
  51. Antiphospholipid antibodies: effects on trophoblast and endothelial cells. D'Ippolito S, Di Simone N, Di Nicuolo F, Castellani R, Caruso A. Am. J. Reprod. Immunol. 58 150-158 (2007)
  52. Clinical relevance of β₂-glycoprotein-I plasma levels in antiphospholipid syndrome (APS). Banzato A, Pengo V. Curr Rheumatol Rep 16 424 (2014)
  53. Detection and characterization of B cell epitopes on beta2-glycoprotein I. Cockerill KA, Linnik MD, Iverson GM. Clin. Immunol. 112 129-135 (2004)
  54. The Michael Mason Prize: Pathogenic antiphospholipid antibodies, stressed out antigens and the deployment of decoys. Ioannou Y. Rheumatology (Oxford) 51 32-36 (2012)
  55. Advances in understanding what we measure when detecting anticardiolipin autoantibodies. Iverson GM, Victoria EJ, Cockerill KA, Linnik MD. Clin. Chim. Acta 343 37-44 (2004)
  56. Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome. Radic M, Pattanaik D. Front Immunol 9 969 (2018)
  57. Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders. Cines DB, McCrae KR, Zheng XL, Sachais BS, Luning Prak ET, Siegel DL. Blood 120 4134-4142 (2012)
  58. Effects of anti-beta 2-glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome. Fierro JJ, Velásquez M, Cadavid AP, de Leeuw K. Am J Reprod Immunol 87 e13509 (2022)
  59. Antiphospholipid Antibodies: Their Origin and Development. Lackner KJ, Müller-Calleja N. Antibodies (Basel) 5 (2016)
  60. β2GP1, Anti-β2GP1 Antibodies and Platelets: Key Players in the Antiphospholipid Syndrome. Ho YC, Ahuja KDK, Körner H, Adams MJ. Antibodies (Basel) 5 (2016)

Articles citing this publication (104)

  1. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, Tobar A, Shoenfeld Y. J. Clin. Invest. 109 797-804 (2002)
  2. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Agar C, van Os GM, Mörgelin M, Sprenger RR, Marquart JA, Urbanus RT, Derksen RH, Meijers JC, de Groot PG. Blood 116 1336-1343 (2010)
  3. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. Jokiranta TS, Jaakola VP, Lehtinen MJ, Pärepalo M, Meri S, Goldman A. EMBO J. 25 1784-1794 (2006)
  4. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Blood 112 1687-1695 (2008)
  5. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. Fitzgerald ML, Morris AL, Chroni A, Mendez AJ, Zannis VI, Freeman MW. J. Lipid Res. 45 287-294 (2004)
  6. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Rand JH, Wu XX, Quinn AS, Chen PP, McCrae KR, Bovill EG, Taatjes DJ. Am. J. Pathol. 163 1193-1200 (2003)
  7. Annexin A2 heterotetramer: structure and function. Bharadwaj A, Bydoun M, Holloway R, Waisman D. Int J Mol Sci 14 6259-6305 (2013)
  8. RETRACTED: Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Murthy KH, Smith SA, Ganesh VK, Judge KW, Mullin N, Barlow PN, Ogata CM, Kotwal GJ. Cell 104 301-311 (2001)
  9. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Arthritis Rheum. 56 280-290 (2007)
  10. Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Ioannou Y, Zhang JY, Passam FH, Rahgozar S, Qi JC, Giannakopoulos B, Qi M, Yu P, Yu DM, Hogg PJ, Krilis SA. Blood 116 1961-1970 (2010)
  11. Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. Aldaz-Carroll L, Whitbeck JC, Ponce de Leon M, Lou H, Hirao L, Isaacs SN, Moss B, Eisenberg RJ, Cohen GH. J. Virol. 79 6260-6271 (2005)
  12. Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Smith BO, Mallin RL, Krych-Goldberg M, Wang X, Hauhart RE, Bromek K, Uhrin D, Atkinson JP, Barlow PN. Cell 108 769-780 (2002)
  13. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Ioannou Y, Zhang JY, Qi M, Gao L, Qi JC, Yu DM, Lau H, Sturgess AD, Vlachoyiannopoulos PG, Moutsopoulos HM, Rahman A, Pericleous C, Atsumi T, Koike T, Heritier S, Giannakopoulos B, Krilis SA. Arthritis Rheum. 63 2774-2782 (2011)
  14. Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. Hammel M, Kriechbaum M, Gries A, Kostner GM, Laggner P, Prassl R. J. Mol. Biol. 321 85-97 (2002)
  15. Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant. Yasuda S, Atsumi T, Matsuura E, Kaihara K, Yamamoto D, Ichikawa K, Koike T. Arthritis Rheum. 52 212-218 (2005)
  16. Endometrial fluid is a specific and non-invasive biological sample for protein biomarker identification in endometriosis. Ametzazurra A, Matorras R, García-Velasco JA, Prieto B, Simón L, Martínez A, Nagore D. Hum. Reprod. 24 954-965 (2009)
  17. {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Sikara MP, Routsias JG, Samiotaki M, Panayotou G, Moutsopoulos HM, Vlachoyiannopoulos PG. Blood 115 713-723 (2010)
  18. Associative and structural properties of the region of complement factor H encompassing the Tyr402His disease-related polymorphism and its interactions with heparin. Fernando AN, Furtado PB, Clark SJ, Gilbert HE, Day AJ, Sim RB, Perkins SJ. J. Mol. Biol. 368 564-581 (2007)
  19. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. Shoenfeld Y, Krause I, Kvapil F, Sulkes J, Lev S, von Landenberg P, Font J, Zaech J, Cervera R, Piette JC, Boffa MC, Khamashta MA, Bertolaccini ML, Hughes GR, Youinou P, Meroni PL, Pengo V, Alves JD, Tincani A, Szegedi G, Lakos G, Sturfelt G, Jönsen A, Koike T, Sanmarco M, Ruffatti A, Ulcova-Gallova Z, Praprotnik S, Rozman B, Lorber M, Vriezman VB, Blank M. J. Clin. Immunol. 23 377-383 (2003)
  20. Letter Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Giannakopoulos B, Hughes WE, Hogg PJ, Krilis SA. Blood 116 1995-1997 (2010)
  21. Solution structure and dynamics of the central CCP module pair of a poxvirus complement control protein. Henderson CE, Bromek K, Mullin NP, Smith BO, Uhrín D, Barlow PN. J. Mol. Biol. 307 323-339 (2001)
  22. The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA. Iverson GM, Matsuura E, Victoria EJ, Cockerill KA, Linnik MD. J. Autoimmun. 18 289-297 (2002)
  23. Interdomain contact regions and angles between adjacent short consensus repeat domains. Lehtinen MJ, Meri S, Jokiranta TS. J. Mol. Biol. 344 1385-1396 (2004)
  24. The extended multidomain solution structures of the complement protein Crry and its chimeric conjugate Crry-Ig by scattering, analytical ultracentrifugation and constrained modelling: implications for function and therapy. Aslam M, Guthridge JM, Hack BK, Quigg RJ, Holers VM, Perkins SJ. J. Mol. Biol. 329 525-550 (2003)
  25. Identification of the phospholipid-binding site of human beta(2)-glycoprotein I domain V by heteronuclear magnetic resonance. Hoshino M, Hagihara Y, Nishii I, Yamazaki T, Kato H, Goto Y. J. Mol. Biol. 304 927-939 (2000)
  26. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions. Gilbert HE, Asokan R, Holers VM, Perkins SJ. J. Mol. Biol. 362 1132-1147 (2006)
  27. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. Ceraudo E, Murail S, Tan YV, Lacapère JJ, Neumann JM, Couvineau A, Laburthe M. Mol. Endocrinol. 22 147-155 (2008)
  28. β₂-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Gropp K, Weber N, Reuter M, Micklisch S, Kopka I, Hallström T, Skerka C. Blood 118 2774-2783 (2011)
  29. Andes virus antigens are shed in urine of patients with acute hantavirus cardiopulmonary syndrome. Godoy P, Marsac D, Stefas E, Ferrer P, Tischler ND, Pino K, Ramdohr P, Vial P, Valenzuela PD, Ferrés M, Veas F, López-Lastra M. J. Virol. 83 5046-5055 (2009)
  30. Hybridomas expressing gammadelta T-cell receptors respond to cardiolipin and beta2-glycoprotein 1 (apolipoprotein H). Born WK, Vollmer M, Reardon C, Matsuura E, Voelker DR, Giclas PC, O'Brien RL. Scand. J. Immunol. 58 374-381 (2003)
  31. Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome. Blank M, Krause I, Magrini L, Spina G, Kalil J, Jacobsen S, Thiesen HJ, Cunningham MW, Guilherme L, Shoenfeld Y. Rheumatology (Oxford) 45 833-841 (2006)
  32. Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies. Safa O, Esmon CT, Esmon NL. Blood 106 1629-1635 (2005)
  33. Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. Sakai T, Balasubramanian K, Maiti S, Halder JB, Schroit AJ. Am. J. Pathol. 171 1659-1669 (2007)
  34. Antigenic structures recognized by anti-beta2-glycoprotein I auto-antibodies. Kasahara H, Matsuura E, Kaihara K, Yamamoto D, Kobayashi K, Inagaki J, Ichikawa K, Tsutsumi A, Yasuda S, Atsumi T, Yasuda T, Koike T. Int. Immunol. 17 1533-1542 (2005)
  35. Induction of anti-β2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. van Os GM, Meijers JC, Agar Ç, Seron MV, Marquart JA, Åkesson P, Urbanus RT, Derksen RH, Herwald H, Mörgelin M, D E Groot PG. J. Thromb. Haemost. 9 2447-2456 (2011)
  36. Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs. Pelkmans L, Kelchtermans H, de Groot PG, Zuily S, Regnault V, Wahl D, Pengo V, de Laat B. PLoS ONE 8 e71402 (2013)
  37. Evolutionary conservation of the lipopolysaccharide binding site of β₂-glycoprotein I. Ağar Ç, de Groot PG, Marquart JA, Meijers JC. Thromb. Haemost. 106 1069-1075 (2011)
  38. Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids. Lee CJ, De Biasio A, Beglova N. Structure 18 366-376 (2010)
  39. Cross-reactive epitopes on beta2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome. Krause I, Blank M, Cervera R, Font J, Matthias T, Pfeiffer S, Wies I, Fraser A, Shoenfeld Y. Ann. N. Y. Acad. Sci. 1108 481-488 (2007)
  40. Lack of association of beta2-glycoprotein I polymorphisms Val247Leu and Trp316Ser with antiphospholipid antibodies in patients with thrombosis and pregnancy complications. Camilleri RS, Mackie IJ, Humphries SE, Machin SJ, Cohen H. Br. J. Haematol. 120 1066-1072 (2003)
  41. In vivo modulation of angiogenesis by beta 2 glycoprotein I. Passam FH, Qi JC, Tanaka K, Matthaei KI, Krilis SA. J. Autoimmun. 35 232-240 (2010)
  42. β2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. Reed JH, Clancy RM, Purcell AW, Kim MY, Gordon TP, Buyon JP. J. Immunol. 187 520-526 (2011)
  43. Cell surface adhesion of pregnancy-associated plasma protein-A is mediated by four clusters of basic residues located in its third and fourth CCP module. Weyer K, Overgaard MT, Laursen LS, Nielsen CG, Schmitz A, Christiansen M, Sottrup-Jensen L, Giudice LC, Oxvig C. Eur. J. Biochem. 271 1525-1535 (2004)
  44. Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318. Shi T, Giannakopoulos B, Iverson GM, Cockerill KA, Linnik MD, Krilis SA. J. Biol. Chem. 280 907-912 (2005)
  45. β2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions. Pozzi N, Acquasaliente L, Frasson R, Cristiani A, Moro S, Banzato A, Pengo V, Scaglione GL, Arcovito A, De Cristofaro R, De Filippis V. J. Thromb. Haemost. 11 1093-1102 (2013)
  46. Capillary electrophoresis-based analysis of phospholipid and glycosaminoglycan binding by human beta2-glycoprotein I. Bohlin ME, Kogutowska E, Blomberg LG, Heegaard NH. J Chromatogr A 1059 215-222 (2004)
  47. Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine. Stafford JH, Hao G, Best AM, Sun X, Thorpe PE. PLoS ONE 8 e84864 (2013)
  48. Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity. Dienava-Verdoold I, Boon-Spijker MG, de Groot PG, Brinkman HJ, Voorberg J, Mertens K, Derksen RH, de Laat B. J. Thromb. Haemost. 9 738-747 (2011)
  49. Plasma gelsolin facilitates interaction between β2 glycoprotein I and α5β1 integrin. Bohgaki M, Matsumoto M, Atsumi T, Kondo T, Yasuda S, Horita T, Nakayama KI, Okumura F, Hatakeyama S, Koike T. J. Cell. Mol. Med. 15 141-151 (2011)
  50. Raising the active site of factor VIIa above the membrane surface reduces its procoagulant activity but not factor VII autoactivation. Waters EK, Yegneswaran S, Morrissey JH. J Biol Chem 281 26062-26068 (2006)
  51. β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. Tanimura K, Jin H, Suenaga T, Morikami S, Arase N, Kishida K, Hirayasu K, Kohyama M, Ebina Y, Yasuda S, Horita T, Takasugi K, Ohmura K, Yamamoto K, Katayama I, Sasazuki T, Lanier LL, Atsumi T, Yamada H, Arase H. Blood 125 2835-2844 (2015)
  52. Binding of plasma proteins to titanium dioxide nanotubes with different diameters. Kulkarni M, Flašker A, Lokar M, Mrak-Poljšak K, Mazare A, Artenjak A, Čučnik S, Kralj S, Velikonja A, Schmuki P, Kralj-Iglič V, Sodin-Semrl S, Iglič A. Int J Nanomedicine 10 1359-1373 (2015)
  53. Screening Outside the Catalytic Site: Inhibition of Macromolecular Inter-actions Through Structure-Based Virtual Ligand Screening Experiments. Sperandio O, Miteva MA, Segers K, Nicolaes GA, Villoutreix BO. Open Biochem J 2 29-37 (2008)
  54. The role of introns in repeat protein gene formation. Street TO, Rose GD, Barrick D. J. Mol. Biol. 360 258-266 (2006)
  55. Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I. Pozzi N, Banzato A, Bettin S, Bison E, Pengo V, De Filippis V. Protein Sci. 19 1065-1078 (2010)
  56. Tolerogenic dendritic cells specific for β2-glycoprotein-I Domain-I, attenuate experimental antiphospholipid syndrome. Zandman-Goddard G, Pierangeli SS, Gertel S, Blank M. J. Autoimmun. 54 72-80 (2014)
  57. Anti-beta2-glycoprotein I autoantibodies require an antigen density threshold, consistent with divalent binding. Reddel SW, Wang YX, Krilis SA. Lupus 12 37-45 (2003)
  58. Cloning and characterization of the human beta2-glycoprotein I (beta2-GPI) gene promoter: roles of the atypical TATA box and hepatic nuclear factor-1alpha in regulating beta2-GPI promoter activity. Wang HH, Chiang AN. Biochem. J. 380 455-463 (2004)
  59. Correlation between beta-2-glycoprotein I gene polymorphism and anti-beta-2 glycoprotein I antibodies in patients with multibacillary leprosy. Brochado MJ, Figueiredo JF, Mendes-Junior CT, Louzada-Junior P, Kim OM, Roselino AM. Arch. Dermatol. Res. 302 583-591 (2010)
  60. Protein extraction and 2-DE of water- and lipid-soluble proteins from bovine pericardium, a low-cellularity tissue. Griffiths LG, Choe L, Lee KH, Reardon KF, Orton EC. Electrophoresis 29 4508-4515 (2008)
  61. Reduced beta2-glycoprotein I protects macrophages from ox-LDL-induced foam cell formation and cell apoptosis. Wang WL, Meng ZX, Zhou SJ, Li CJ, Chen R, Lv L, Ma ZJ, Yu DM, Yu P. Lipids Health Dis 12 174 (2013)
  62. Amino acid patterns within short consensus repeats define conserved duplicons shared by genes of the RCA complex. McLure CA, Dawkins RL, Williamson JF, Davies RA, Berry J, Natalie LJ, Laird R, Gaudieri S. J. Mol. Evol. 59 143-157 (2004)
  63. Attachment of beta 2-glycoprotein I to negatively charged liposomes may prevent the release of daughter vesicles from the parent membrane. Urbanija J, Babnik B, Frank M, Tomsic N, Rozman B, Kralj-Iglic V, Iglic A. Eur. Biophys. J. 37 1085-1095 (2008)
  64. Comprehensive evaluation of apolipoprotein H gene (APOH) variation identifies novel associations with measures of lipid metabolism in GENOA. Leduc MS, Shimmin LC, Klos KL, Hanis C, Boerwinkle E, Hixson JE. J. Lipid Res. 49 2648-2656 (2008)
  65. Effects of ionic strength, temperature and conformation on affinity interactions of β₂-glycoprotein I monitored by capillary electrophoresis. Bohlin ME, Blomberg LG, Heegaard NH. Electrophoresis 32 728-737 (2011)
  66. Percentile-based spread: a more accurate way to compare crystallographic models. Pozharski E. Acta Crystallogr. D Biol. Crystallogr. 66 970-978 (2010)
  67. Human apolipoprotein H may have various orientations when attached to lipid layer. Wang F, Xia XF, Sui SF. Biophys. J. 83 985-993 (2002)
  68. Reduced beta 2 glycoprotein I improves diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway. Wang T, Chen SS, Chen R, Yu DM, Yu P. Int J Clin Exp Pathol 8 2321-2333 (2015)
  69. Agglutination of like-charged red blood cells induced by binding of beta2-glycoprotein I to outer cell surface. Lokar M, Urbanija J, Frank M, Hägerstrand H, Rozman B, Bobrowska-Hägerstrand M, Iglic A, Kralj-Iglic V. Bioelectrochemistry 73 110-116 (2008)
  70. Comment "Resurrection of thrombin" in the pathophysiology of the antiphospholipid syndrome. Koike T, Atsumi T. Arthritis Rheum. 56 393-394 (2007)
  71. Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. Bourke LT, McDonnell T, McCormick J, Pericleous C, Ripoll VM, Giles I, Rahman A, Stephanou A, Ioannou Y. Cell Death Dis 8 e2549 (2017)
  72. Beta-2-glycoprotein I is growth regulated and plays a role as survival factor for hepatocytes. Averna M, Paravizzini G, Marino G, Emmanuele G, Cefalù AB, Magro G, Bartoloni G, Ragusa M, Noto D, Barbagallo CM, Callari D, Mazzarino MC, Notarbartolo A, Travali S. Int. J. Biochem. Cell Biol. 36 1297-1305 (2004)
  73. Biophysical analysis of the interaction of the serum protein human β2GPI with bacterial lipopolysaccharide. Gries A, Prassl R, Fukuoka S, Rössle M, Kaconis Y, Heinbockel L, Gutsmann T, Brandenburg K. FEBS Open Bio 4 432-440 (2014)
  74. Contamination of therapeutic human immunoglobulin preparations with apolipoprotein H (β2-glycoprotein I). Lackner F, Beck G, Eichmeir S, Gemeiner M, Hummel K, Pullirsch D, Razzazi-Fazeli E, Seifner A, Miller I. Electrophoresis 35 515-521 (2014)
  75. Covalent attachment of functionalized cardiolipin on a biosensor gold surface allows repetitive measurements of anticardiolipin antibodies in serum. Schlichtiger A, Baier C, Yin MX, Holmes AB, Maruyama M, Strasser R, Rant U, Thaler M, Luppa PB. Anal Bioanal Chem 405 275-285 (2013)
  76. Identification of APOH polymorphisms as common genetic risk factors for venous thrombosis in the Chinese population. Tang L, Zeng W, Lu X, Wang QY, Liu H, Cheng ZP, Wu YY, Hu B, Jian XR, Guo T, Wang HF, Hu Y. J. Thromb. Haemost. 12 1616-1625 (2014)
  77. Reduced beta 2 glycoprotein I improve diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway. Wang T, Chen SS, Chen R, Yu DM, Yu P. Int J Clin Exp Med 8 6852-6865 (2015)
  78. Standardized antigen preparation to achieve comparability of anti-beta2-glycoprotein I assays. Müller C, Schlichtiger A, Balling G, Steigerwald U, Luppa PB, Thaler M. Thromb. Res. 126 e102-9 (2010)
  79. Anti-cardiolipin/beta-2 glycoprotein activities co-exist on human anti-DNA antibody light chains. Kumar S, Nagl S, Kalsi JK, Ravirajan CT, Athwal D, Latchman DS, Pearl LH, Isenberg DA. Mol. Immunol. 40 517-530 (2003)
  80. Autoantibody response and pregnancy-related pathology induced by combined LPS and tetanus toxoid hyperimmunization in BALB/c and C57BL/6 mice. Petrušić V, Todorović N, Živković I, Dimitrijević R, Muhandes L, Rajnpreht I, Dimitrijević L. Autoimmunity 48 87-99 (2015)
  81. Estimation of the amount of β2-glycoprotein I adsorbed at the inner surface of fused silica capillaries after acidic, neutral and alkaline pretreatment. Bohlin ME, Johannesson I, Carlsson G, Heegaard NH, Blomberg LG. Electrophoresis 33 1695-1702 (2012)
  82. Human β2-glycoprotein I attenuates mouse intestinal ischemia/reperfusion induced injury and inflammation. Tomasi M, Hiromasa Y, Pope MR, Gudlur S, Tomich JM, Fleming SD. Mol. Immunol. 52 207-216 (2012)
  83. Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I. Artenjak A, Locatelli I, Brelih H, Simonič DM, Ulcova-Gallova Z, Swadzba J, Musial J, Iwaniec T, Stojanovich L, Conti F, Valesini G, Avčin T, Cohen Tervaert JW, Shoenfeld Y, Blank M, Ambrožič A, Sodin-Semrl S, Božič B, Čučnik S. Immunol. Res. 61 35-44 (2015)
  84. Beta-2-glycoprotein specificity of human anti-phospholipid antibody resides on the light chain: a novel mechanism for acquisition of cross-reactivity by an autoantibody. Kumar S, Nagl S, Kalsi JK, Ravirajan CT, Athwal D, Latchman DS, Pearl LH, Isenberg DA. Mol. Immunol. 42 39-48 (2005)
  85. Optimization of unnicked β2-glycoprotein I and high avidity anti-β2-glycoprotein I antibodies isolation. Artenjak A, Leonardi A, Križaj I, Ambrožič A, Sodin-Semrl S, Božič B, Cučnik S. J Immunol Res 2014 195687 (2014)
  86. Quantifying In Situ Structural Stabilities of Human Blood Plasma Proteins Using a Novel Iodination Protein Stability Assay. Lin HL, James I, Hyer CD, Haderlie CT, Zackrison MJ, Bateman TM, Berg M, Park JS, Daley SA, Zuniga Pina NR, Tseng YJ, Moody JD, Price JC. J Proteome Res 21 2920-2935 (2022)
  87. Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of beta2-glycoprotein I (apolipoprotein H). Mehdi H, Naqvi A, Kamboh MI. Biochim. Biophys. Acta 1782 163-168 (2008)
  88. Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN. Zhang JY, Ma J, Yu P, Tang GJ, Li CJ, Yu DM, Zhang QM. Am J Transl Res 9 3935-3949 (2017)
  89. Relative quantification of several plasma proteins during liver transplantation surgery. Parviainen V, Joenväärä S, Tukiainen E, Ilmakunnas M, Isoniemi H, Renkonen R. J. Biomed. Biotechnol. 2011 248613 (2011)
  90. [Val247Leu polymorphism of beta2 glycoprotein 1 gene may justify the genesis of anti beta2GP1 antibodies and antiphospholipid syndrome in multibacillary leprosy]. Brochado MJ, Nascimento MM, Louzada Junior P, Figueiredo JF, Roselino AM. An Bras Dermatol 84 355-359 (2009)
  91. A snappy new concept for APS. Rand JH. Blood 116 1193-1194 (2010)
  92. An allosteric redox switch in domain V of β2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. Kumar S, Chinnaraj M, Planer W, Zuo X, Macor P, Tedesco F, Pozzi N. J Biol Chem 297 100890 (2021)
  93. Effects of reduced β2 glycoprotein I on high glucose‑induced cell death in HUVECs. Zhang JY, Ma J, Yu P, Tang GJ, Li CJ, Yu DM, Zhang QM. Mol Med Rep 16 4208-4214 (2017)
  94. Lysine residues control the conformational dynamics of beta 2-glycoprotein I. Buchholz I, Nestler P, Köppen S, Delcea M. Phys Chem Chem Phys 20 26819-26829 (2018)
  95. Oxidation of β2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. Raimondo MG, Pericleous C, Radziszewska A, Borghi MO, Pierangeli S, Meroni PL, Giles I, Rahman A, Ioannou Y. PLoS ONE 12 e0186513 (2017)
  96. Pathogenesis of antiphospholipid syndrome: recent insights and emerging concepts. Lackner KJ, Müller-Calleja N. Expert Rev Clin Immunol 15 199-209 (2019)
  97. Structural and functional characterization of β2 -glycoprotein I domain 1 in anti-melanoma cell migration. Leu SJ, Lee TY, Cheng SW, Tsai MY, Lin YS, Chiou TJ, Huang KY, Chiang AN. Cancer Sci. 110 1974-1986 (2019)
  98. The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study. Yao WC, Leong KH, Chiu LT, Chou PY, Wu LC, Chou CY, Kuo CF, Tsai SY. Thromb J 20 50 (2022)
  99. Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes. Tanimura K, Saito S, Tsuda S, Ono Y, Ota H, Wada S, Deguchi M, Nakatsuka M, Nagamatsu T, Fujii T, Kobashi G, Arase H, Yamada H. Int J Mol Sci 24 10958 (2023)
  100. Detection of Enteric Viruses on Strawberries and Raspberries Using Capture by Apolipoprotein H. Lévesque A, Jubinville E, Hamon F, Jean J. Foods 10 3139 (2021)
  101. Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome. El-Assaad F, Krilis SA, Giannakopoulos B. Thromb J 14 20 (2016)
  102. Recombinant domain V of β2-glycoprotein I inhibits the formation of a 7-ketocholesteryl-9-carboxynonanoate and β2-glycoprotein I complex. Zhang Y, Li W, Chi Y, Wang R, Wang D, Zhang F, Liu Z, Matsuura E, Liu Q. J. Biochem. 149 35-42 (2011)
  103. Structural model of haptoglobin and its complex with the anticoagulant ecotin variants: structure-activity relationship study and analysis of interactions. Sathler PC, Lourenço AL, Miceli LA, Rodrigues CR, Albuquerque MG, Cabral LM, Castro HC. J Enzyme Inhib Med Chem 29 256-262 (2014)
  104. Thrombomodulatory Effect of Anti-B2-Glycoprotein I Antibodies on Crystalline Annexin A5 on Phospholipid Bilayers, as Observed by Atomic Force Microscopy. Irman Š, Škarabot M, Muševič I, Rozman B, Božič B. EJIFCC 21 81-93 (2011)


Related citations provided by authors (1)

  1. Crystallization and preliminary X-ray crystallographic studies on apolipoprotein H (beta2-glycoprotein-I) from human plasma.. Saxena A, Gries A, Schwarzenbacher R, Kostner GM, Laggner P, Prassl R Acta Crystallogr D Biol Crystallogr 54 1450-2 (1998)

Quick links